To develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for MDR P. Aeruginosa infections.

Active Definitive Contract Awarded Last action

Contract number
75N93020C00019
Awardee
Awarding agency
Obligated
$7,263,391

Award facts

Opportunity
Contract value 95% obligated
  • $7,263,391.00 Current, with exercised options
  • $7,621,277.00 Potential, with all options
Completion date 78% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 12 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Worcester, MA 01605, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00017 $0
Other Administrative Action P00016 $0
Other Administrative Action P00015 $0
Exercise an Option P00014 $2,742,219
Other Administrative Action P00013 $0
Exercise an Option P00012 $2,485,753
Other Administrative Action P00011 $0
Other Administrative Action P00010 $0
Exercise an Option P00009 $830,880
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Funding Only Action P00006 $299,643
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $904,896
Show all 18

About this award

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases awarded a $7.62 million definitive contract to Microbiotix, Inc. on July 1, 2020, to develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for multidrug-resistant Pseudomonas aeruginosa infections.

The contract is cost-plus-fixed-fee and carries no set-aside. Place of performance is Worcester, MA. The originating solicitation emerged from a NIAID Broad Agency Announcement posted in January 2019 seeking proposals for development of radiation and nuclear medical countermeasures, though the awarded work focuses on bacterial secretion system inhibitors for drug-resistant infections. Performance extends through July 28, 2028.

Government invoicing under this contract reflects a labor footprint that grew significantly in FY2023, when reported work reached 104 FTEs and 215,795 contractor hours, then moderated to 3.2 FTEs and derived government-paid rates in the $200–348/hr range across subsequent years. FY2025 reported 3.2 FTEs with no subcontractors; Microbiotix self-performed all reported hours. The derived hourly rate trend is rising.

Quick answers

Who was awarded contract 75N93020C00019?

75N93020C00019 was awarded to Microbiotix, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.

How much is contract 75N93020C00019 worth?

The government has obligated $7,263,391 on 75N93020C00019. Its potential value, with all options, is $7,621,277.

Was contract 75N93020C00019 competed?

The extent of competition for 75N93020C00019 was full and open competition. The government received 12 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login